13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001791827
Total reported value
$624.4M
$624.4M
87 檔
122.8%
In Q1 2024, Avidity Partners Management LP's U.S. equity holdings reached a combined market value of $624.4M, distributed across 87 disclosed stock positions.
During Q1 2024, Avidity Partners Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 9.06% | — | +69.01% | |
| 2 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 4.47% | — | — | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.32% | -0.21% | +3.49% | |
| 4 | ARVN | Arvinas Inc | Stock-Other | 3.97% | — | +0.00% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.91% | — | +165.88% | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.63% | -2.91% | +123.20% | |
| 7 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 2.57% | — | -13.11% | |
| 8 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.39% | — | -18.46% | |
| 9 | NTRA | Natera Inc | Stock-Healthcare | 2.37% | -0.36% | EXIT | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 2.27% | — | +19.40% | |
| 11 | AVTR | Avantor Inc | Stock-Healthcare | 2.22% | — | +27.01% | |
| 12 | CI | THE Cigna Group | Stock-Healthcare | 2.16% | — | -47.29% | |
| 13 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.14% | — | — | |
| 14 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.11% | — | — | |
| 15 | CGON | Cg Oncology Inc | Stock-Other | 2.06% | -1.75% | — | |
| 16 | ILMN | Illumina Inc | Stock-Healthcare | 2.05% | — | — | |
| 17 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.04% | — | -31.00% | |
| 18 | ALGN | Align Technology Inc | Stock-Healthcare | 2.00% | — | +21.31% | |
| 19 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.85% | — | -38.92% | |
| 20 | LLY | Eli Lilly & Co | Stock-Healthcare | 1.76% | — | -17.65% | |
| 21 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.73% | — | — | |
| 22 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.61% | — | -8.52% | |
| 23 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 1.50% | — | — | |
| 24 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.41% | — | +10.54% | |
| 25 | CVS | Cvs Health CORP | Stock-Healthcare | 1.40% | — | -26.35% | |
| 26 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.40% | +0.55% | -39.64% | |
| 27 | SGRY | Surgery Partners Inc | Stock-Other | 1.39% | — | +23.94% | |
| 28 | ABBV | Abbvie Inc | Stock-Healthcare | 1.33% | — | -20.18% | |
| 29 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.30% | — | -30.73% | |
| 30 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.21% | +0.07% | NEW | |
| 31 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.17% | — | — | |
| 32 | DHR | Danaher CORP | Stock-Healthcare | 1.16% | — | -50.41% | |
| 33 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.13% | — | -47.39% | |
| 34 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.11% | — | -6.18% | |
| 35 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.99% | — | -12.99% | |
| 36 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.96% | — | +26.32% | |
| 37 | CRBU | Caribou Biosciences Inc | Stock-Other | 0.96% | — | -9.04% | |
| 38 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.93% | — | — | |
| 39 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.89% | — | -40.38% | |
| 40 | RGNX | Regenxbio Inc | Stock-Other | 0.88% | — | — | |
| 41 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 42 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.80% | — | -9.58% | |
| 43 | DXCM | Dexcom Inc | Stock-Healthcare | 0.79% | -0.06% | — | |
| 44 | NGNE | Neurogene Inc | Stock-Other | 0.76% | — | -0.22% | |
| 45 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.72% | — | — | |
| 46 | IMNM | Immunome Inc | Stock-Other | 0.70% | — | -34.47% | |
| 47 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.69% | — | -79.96% | |
| 48 | GKOS | Glaukos CORP | Stock-Healthcare | 0.68% | — | — | |
| 49 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.66% | -0.30% | EXIT | |
| 50 | PCVX | Vaxcyte Inc | Stock-Other | 0.63% | — | -50.19% |
According to official SEC Form 13F filings, Avidity Partners Management LP reported a total U.S. public equity portfolio value of $624.4M across 87 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ITCIEUR, FUSION PHARMACEUTICALS INC, BSX) accounted for 122.8% of total reported equity market value during Q1 2024.
During Q1 2024, Avidity Partners Management LP's top holdings by market value included ITCIEUR (9.1%)、FUSION PHARMACEUTICALS INC (4.5%)、BSX (4.3%). The largest single position, ITCIEUR, represented 9.1% of total portfolio value.
In Q1 2024, Avidity Partners Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.